Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carina A Rodriguez

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Child and Adolescent Psychopharmacology|October 15, 2014
Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotypeTanya K Murphy, Priyal D Patel, Joseph F McGuire, et al.
The Lancet. Child & Adolescent Health|July 24, 2021
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trialAditya H Gaur, Mark F Cotton, Carina A Rodriguez, et al.
The Journal of Infectious Diseases|October 10, 2025
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic StudyEdward P Acosta, Inmaculada Aban, Kevin J Ryan, et al.
The Lancet. HIV|April 15, 2024
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm studyCarina A Rodriguez, Eva Natukunda, Renate Strehlau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2024
Safety and Immunogenicity of an mRNA-1273 Booster in ChildrenVladimir Berthaud, C Buddy Creech, Christina A Rostad, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Child and Adolescent Psychopharmacology|October 15, 2014
Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotypeTanya K Murphy, Priyal D Patel, Joseph F McGuire, et al.
The Lancet. Child & Adolescent Health|July 24, 2021
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trialAditya H Gaur, Mark F Cotton, Carina A Rodriguez, et al.
The Journal of Infectious Diseases|October 10, 2025
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic StudyEdward P Acosta, Inmaculada Aban, Kevin J Ryan, et al.
The Lancet. HIV|April 15, 2024
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm studyCarina A Rodriguez, Eva Natukunda, Renate Strehlau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2024
Safety and Immunogenicity of an mRNA-1273 Booster in ChildrenVladimir Berthaud, C Buddy Creech, Christina A Rostad, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Pageof 3